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In a series of 22 pancreatic acinar ceU carcino-
mas, including two acinar cystadenocarcinomas,
celular differentiation was analyzed by immuno-
cytochemistry and electron microscopy. In addi-
tion, overexpression ofp53 protein and Ki-ras
codon 12 mutation was studied. Four of the 20
noncystic acinar ceU carcinomas showed a pure
acinarpattern, nine an acinar-solid, and seven a
solid pattern. AU tumors stainedfor at least one
of the folowing pancreatic acinar markers:
trypsin (21 of22), lipase (19 of22), chymotrypsin
(13 of 22), phospholipase A2 (nine of 22), and
pancreatic stone protein (19 of22). One-third of
the tumors expressed neuroendocrine markers
(synaptophysin, eight of22; chromogranin A, six
of21) and duct ceUl markers (CA19.9, nine of21;
B72.3, six of21). Celular coexpression oftrypsin
and synaptophysin was demonstrated in one tu-
mor. Electron microscopy revealed zymogen
granules (nine ofnine). In only one of 16 tumors
a Ki-ras mutation atcodon 12 wasfound, whereas
in none of19 tumors could overexpression ofp53
protein be demonstrated. The results suggest that
acinar ceU carcinomas show obvious capacity to
differentiate into several directions, but neverthe-
less constitute an entity differentfrom ductal ad-
enocarcinomas or endocrine tumors. (Am J
Pathol 1993, 143:685-698)
Acinar cell carcinoma is uncommon, with a reported
incidence of 1% among tumors of the exocrine pan-
creas. 1,2 Because of its acinar differentiation, which is
evident from histological features, ultrastructural
demonstration of zymogen granules, immunostaining
for pancreatic enzymes, and occasional secretion of
lipase into the serum, 1,3-7 it is believed to derive from
transformed acinar cells.3
In recent years, acinar cell carcinomas have been
studied in more detail.6`9 From these investigations,
it emerged that histologically some of the acinar cell
carcinomas are extremely difficult to distinguish from
neuroendocrine tumors.7'10'11 Moreover, immunocy-
tochemical studies showed that neuroendocrine
markers (ie, synaptophysin and chromogranin A) may
be expressed by acinar cell carcinomas,7'12 whereas
pancreatic enzymes such as trypsin were found in
ductal adenocarcinomas.13
In the present study, a series of 22 pancreatic aci-
nar cell carcinomas was analyzed using techniques
of immunocytochemistry, electron microscopy, and
molecular biology. In particular, we addressed the fol-
lowing questions: 1) which are the histological and
immunocytochemical features most relevant to the di-
agnosis; 2) how often is a mixed exocrine-endocrine
differentiation present; and 3) do acinar cell carcino-
mas show a rate of p53 protein overexpression and
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Ki-ras oncogene activation similar to that of ductal
adenocarcinomas?1415
Material and Methods
We investigated a series of 22 pancreatic tumors
with acinar cell differentiation -from different hospi-
tals in Europe (n = 15), Japan (n = 6), and the
United States (n = 1). The series consisted of 20
acinar cell carcinomas and two acinar cystadeno-
carcinomas. The most important clinicopathological
findings of the patients are summarized in Table 1.
Patients nos. 1, 2, 5, 6, and 21 have been included
in earlier studies316 and were investigated again
with respect to the histological differentiation, immu-
nocytochemical profile, p53 overexpression, and Ki-
ras mutation at codon 12.
All but one (a 16-year-old girl) of the 20 patients
with acinar cell carcinoma were adults (age range
28 to 78 years; mean 55 years). The male to female
ratio was 13:7. Of the nine patients with follow-up in-
formation, seven survived four months to 7.5 years
(mean survival two years) after tumor resection. Two
patients were alive 3.5 years after initial diagnosis.
Table 1. Clinicopathological Findings of the Patients
Site (in pancreas)
Body
Tail
Head-body-tail
Adherent to the head
Head-body
Body
Head
Head with invasion of
duodenum
Tail
Adherent to the
pancreas with invasion
of stomach, omentum,
and mesocolon
Body-tail
Tail
Head
Head-body
Adherent to the body,
with invasion of
duodenum
Tail
Head
Head
Head
Tail with invasion of
spleen
Adherent to the body
and tail, extending to
the hilus of the spleen;
no invasion of the
spleen
22t 64/M Body
Size in cm
6 x 7 x 4
3.5 x 3 x 3
diam. 17
30 x 28 x 10
7 x 7 x 5
7x6x5
diam. 7
5 x 5 x 2.5
17 x 10x 12
diam. 12
8 x 6 x 5
diam. 2
diam. 5
19 x 17 x 15
4.5 x 4 x 4
7 x 5 x 5
3 x 4 x 5
10 x 8 x 7
12 x 3 x 3
17 x 15 x 9
Metastasis*
Liver
Lymph nodes,
liver
Lymph nodes,
liver
Not found
Lymph node
metastasis
suspected
Lymph nodes,
liver, lung
Not found
Not found
Liver
Not found
Lymph nodes,
liver
Lymph nodes,
liver
Lymph nodes,
liver
Liver
Not found
Lymph nodes,
liver
Liver
Not found
Lymph nodes,
liver, lung
Liver,
peritoneum
Liver
17x 14x7 Not found
Follow-up
Died 3 years after
diagnosis
Died 1 year after
diagnosis
Died 1 year after
diagnosis
No information
No information
No information
No information
No information
No information
No information
Died 1 year after
diagnosis
No information
Alive 3.5 years
after diagnosis
No information
No information
Died 7.5 years
after diagnosis
Died 1 year after
diagnosis
Alive 3.5 years
after diagnosis
No information
Died 4 months
after diagnosis
16 months after
diagnosis,
development of a
liver metastasis;
alive 2 months
after partial
hepatectomy
No information
* At the time of diagnosis.
t Polyarthralgia and subcutaneous fat necrosis associated with high serum lipase levels.
t Acinar cystadenocarcinoma.
Case no.
2t
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21t
Age/sex
66/F
60/M
60/M
78/M
64/F
64/M
60/M
59/M
64/F
16/F
37/M
49/M
28/F
58/M
51/M
48/M
46/M
74/F
59/F
63/M
42/M
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The acinar cell carcinomas showed no preferential
localization (head: seven of 20; tail: five of 20; dif-
fuse: eight of 20), and their diameters ranged from
2 to 30 cm (mean 10 cm, Figure 1). It is noteworthy
that three of these tumors were found to be at-
tached to the pancreas. Metastases in lymph
nodes, liver, lung, and peritoneum were found in
more than half of the patients at the time of diagno-
sis (Table 1). One patient (a 60-year-old man)
showed high-serum lipase levels, polyarthralgia,
and subcutaneous fat necrosis. One acinar cell
cystadenocarcinoma published nreviously16 oc-
curred in a 42-year-old man. This large tumor (di-
ameter 17 cm) was closely attached to the body
and tail of the pancreas, extended to the hilus of the
spleen, and had metastases in the liver. The patient
was alive 18 months after the initial diagnosis. The
other acinar cell cystadenocarcinoma occurred in a
64-year-old man. The tumor was also large (diame-
ter of 17 cm) and located in the body of the pan-
creas, but showed no metastases. In 19 patients, a
laparotomy was performed and led to the removal
of the tumor in 17 patients. In two patients, only bi-
opsy specimens were obtained from liver or lymph
node metastases. Autopsy specimens were avail-
able from three patients, two of them with previous
biopsies.
All but one (Bouin's solution) tumor specimen were
fixed in 10% formaldehyde. Four-p-thick serial sec-
tions were cut from paraffin-embedded tissue blocks
(one to three per specimen). The first two sections
were stained with hematoxylin and eosin and peri-
odic acid-Schiff (PAS) reagent with diastase pretreat-
ment. Immunocytochemical analysis was carried out
on subsequent sections, with use of the streptavidin-
biotin-peroxidase complex method. The sections
were stained with the primary antisera listed in Table
2. In patient no. 16, only eight sections were avail-
able for immunostaining. Four different antisera
against amylase, three antisera against trypsin, and
two antisera against synaptophysin were used. The
antisera against a-amylase, lipase, trypsin, and chy-
motrypsin were generated as previously reported.3
The histochemical re-action for peroxidase was per-
formed using 3.3 diaminobenzidine-tetrahydrochlo-
ride (0.05% w/v) and hydrogen peroxide (0.01% w/v)
in phosphate-buffered saline buffer. A panel of pan-
creatic ductal cancer cell lines and paraffin-embed-
ded ductal carcinomas with known p53 status was
used as controls for CM1 immunoreactivity. Sections
of normal pancreas were used as positive controls
for the antisera against pancreatic enzymes, neu-
roendocrine markers, pancreatic hormones, and
CAM 5.2; liver sections of a patient with a-i-anti-
trypsin deficiency served as positive control for a-i-
antitrypsin serum; colon carcinomas were used as
positive controls for carcinoembryonic antigen
(CEA), CA 19.9, and B72.3; a hepatocellular carci-
noma was used as a positive control for a-feto pro-
tein (AFP), and a ductal adenocarcinoma of the pan-
creas was used as a positive control for the Ml
antibody. 17 The antisera against pancreatic enzymes
and pancreatic stone protein (PSP) were also tested
on three normal liver tissue specimens, four normal
pancreas tissue specimens, five pancreatic neu-
roendocrine tumors, 10 pancreatic ductal adenocar-
cinomas, and four normal duodenal mucosa speci-
mens (all fixed in 10% formaldehyde). The specificity
of the antibodies against trypsin was tested by pre-
absorbing the antiserum with bovine trypsin (Sigma
Chemical Co., St. Louis, MO). One tumor (patient no.
19) was used for double staining with antisera
against trypsin and synaptophysin. In a first step, we
performed a synaptophysin staining using the
streptavidin-biotin-peroxidase complex method with
3.3-diaminobenzidine-tetrahydrochloride as brown
Figure 1. Acinar cell carcinoma occurring in
the tail of the pancreas of a 63-year-old man
(patient no. 20). Note the nodular appearance
of the tumor (arrows) and invasion of the
spleete.
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Table 2. Antisera
Antigen Antiserum/Code Working dilution Source
Lipase (Lip)
Trypsin (Tryp)
Chymotrypsin
(C-Tryp)
Phospholipase A2
(PLA2)
a amylase
(Amyl)
Pancreatic stone
protein (PSP)
B 72.3
Carbohydrate antigen
19.9
Carcinoembryonic
antigen (CEA)
Mucin antigen
a-fetoprotein
(AFP)
a-i -antitrypsin
(AAT)
Synaptophysin (Syn)
Chromogranin A
(CgA)
Leu 7
Insulin
Glucagon
Somatostatin
Pancreatic
polypeptide
Keratin 8, 18 and 19
p53
p
p
p
M
p
1:1000
1:2000
1:4000
1:100
1:10000
M 1:500
p 1:6000
p
M
p
M
M (4HC Sor 26
Anti-TAG72)
M (CA 19.9)
M
CEA-BMA-1 30b
CEA-BMA-130c
M (Ml)
M
p
p
M (SY38)
M
M
M
M
M
P
M (CAM 5.2)
PC (M1)
1:6000
1:2000
1:500
1:2000
1:20
1:200
1:10
1:8000
diluted solution
1:20
1:100
1:400
diluted solution
1:3
1:5000
1:1000
1:5000
1:50000
1:10
1:500
Own
Own
Ventrex Laboratories, Portland, OR
Ventrex Laboratories, Portland, OR
Own
Dr. T. Nevaleinen, Turku, Finland
Own
Chemicon, Temecula, CA
DRG-Instruments, Marburg,
Germany
Binding Site, Birmingham, UK
Immunotech, Marseille, France
Sorin Biomedica, Brussels,
Belgium
Dr. H. Kalthoff, Hamburg,
Germany
Behring Lab., Marburg, Germany
Dr. E. Solcia, Pavia, Italy
Amersham, Buckinghamshire,
UK
Biogenex, San Ramon, CA
Dr. R. Jahn, New Haven, CT
Dr. B. Wiedenmann, Heidelberg,
Germany
Biogenex, San Ramon, CA
Becton-Dickinson, Mountain
View, CA
Novo, Bagsvaerd, Denmark
Novo, Bagsvaerd, Denmark
Novo, Bagsvaerd, Denmark
Dr. R.E. Chance, Indianapolis, IN
Biogenesis, Bournemouth,
Dr. DP Lane, Dundee, UK
P: Polyclonal
M: Monoclonal
chromogen. Then we stained for trypsin and used
bromo-chloro-indosyl-phosphate (MC Gadey's re-
agent) as blue chromogen.
Electron microscopical examination was per-
formed in seven acinar cell carcinomas and the two
acinar cystadenocarcinomas (patients nos. 7, 11 to
14, 17, 18, 21, and 22). Small tissue pieces were
fixed immediately after tumor tissue removal in
phosphate-buffered glutaraldehyde (2%, pH 7.4),
postfixed in cacodylate-buffered osmium tetroxide
(1%), and embedded in Epon. Ultrathin sections
were stained with uranylacetate and lead citrate
and examined using an JEOL or a Zeiss EM109
electron microscope. Using the postembedding
technique for immunoelectron microscopy, ultrathin
sections of one acinar cell carcinoma (patient no.
14) were incubated with the antiserum against
trypsin at a dilution of 1:2,000 in phosphate-
buffered saline buffer pH 7.4. After washing several
times in phosphate-buffered saline buffer, the sec-
ond incubation was performed with a goat anti-
rabbit antibody coated with 15-nm diameter colloi-
dal gold complex (Janssen Pharmaceutica, Beerse,
Belgium) for 30 minutes at room temperature. Then
the sections were again washed several times and
finally stained with uranylacetate and lead citrate.
The Ki-ras mutation at codon 12 as well as abnor-
malities of p53 tumor suppressor gene were exam-
ined in respectively 16 (patient nos. 1-12, 14, 15,
21, and 22) and 19 tumors (patient nos. 1 to 12, 14,
15, 17, and 19 to 22). Expression of the mutated
p53 protein was analyzed using the CM1 polyclonal
antibody as previously described.18 For detection of
the Ki-ras mutation, genomic DNA was extracted
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from sections cut from paraffin-embedded tissue
blocks by the method described by Jackson et al.19
Briefly, five sections of 10-p thickness were cut from
each block and placed in a sterile Eppendorf tube,
dewaxed in two changes of warm xylene, and
washed twice in alcohol before drying. The tissue
was then resuspended in digestion buffer (100
mmol/L NaCI, 10 mmol/L TrisHCI, 25 mmol/L ethyl-
enediamine tetraacetic acid, 0.5% sodium dodecyl
sulfate, pH 8.4) containing 0.1 mg/ml proteinase K
(Sigma), and incubated at 37 C for 5 days. Nucleic
acid was purified by organic extraction with phenol/
chloroform and then chloroform. The nucleic acid
was then ethanol-precipitated, washed and dried
before dissolving in 200 pl Tris-ethylenediamine tet-
raacetic acid buffer. Ten p1 of sample DNA solution
was used for each polymerase chain reaction (PCR)
amplification. Genomic DNA was amplified in a vol-
ume of 50 or 100 pl containing 50 mmol/L KCI, 10
mmol/L Tris-HCI (pH 8.3), 1.5 mmol/L MgCI2, 0.01%
(w/v) gelatin, 1.25 mmol/L of each of four deoxynu-
cleotide triphosphatase (Pharmacia, Piscataway,
NJ), 0.5 to 1.0 pg of a pair of primers and 2.5 units
of Taq DNA polymerase (Perkin Elmer Cetus, Nor-
walk, CT). The conditions for the PCR using a ther-
mal cycler (Perkin-Elmer Cetus, Vaterstetten, Ger-
many) are as follows: 94 C for 10 minutes for initial
denaturation, 30 cycles of 94 C for 1 minute, an-
nealing for 2 minutes at 45 C, and extension at 68 C
for 2 minutes. Mutation at codon 12 of the Ki-ras on-
cogene was detected by the method of Mitsudomi
et a120 in which mismatched primers (Figure 2) are
used in the PCR reaction to create restriction frag-
ment length polymorphisms. Samples were first
screened for the presence or absence of the wild
type sequence by Banl digestion of DNA produced
by amplification with primers K12S and K12ABan,
and then those samples in which a mutant se-
quence was suspected were further investigated by
amplification with other primer pairs as appropri-
ate.20 Twenty pl of the 100 pl PCR reaction was di-
gested with the appropriate restriction enzyme.
K12S CATGTTCTAATATAGTCACA- -
Banl and Sacl were obtained from Promega Ltd.,
Southampton, UK, Mael and Mbol from Boehringer
Mannheim, Lewes, UK, Fnu4H-1, Hincil, and Hindll
from CP Laboratories, Bishop's Startford, UK. The
reaction conditions followed suppliers' recommen-
dations. The DNA was then electrophoresed
through 2.5% Nusieve/1% agarose gel and the
ethidium bromide-stained gel photographed using
an ultraviolet light transilluminator and a gel docu-
mentation system (UltraViolet Products, Cambridge,
UK). Negative controls included PCR reactions set
up without sample DNA (to exclude contamination
of reagents) and PCR reactions of a series of nor-
mal control DNAs from volunteers. Positive controls
included DNA from a series of pancreatic and co-
lonic cancer cell lines with known mutations at Ki-
rascodon 12.
Results
Histological Findings
Features common to all tumors of this series were a
gross lobulation of the neoplastic tissue by fibrous
strands with very scanty stroma within the large lob-
ules, and a broad invasion into adjacent pancreatic
tissue, the spleen, or the duodenum. The features
that differed from one tumor to the other concerned
the histological pattern and cytological maturation.
Whereas some tumors showed the classical pattern
of acinar cell carcinomas as described in the
literature,1-3,7,21 others presented as more solid, un-
differentiated neoplasms. Because of the apparent
histological heterogeneity, we classified the tumors
(with the exception of the two acinar cystadenocar-
cinomas) into three patterns of differentiation (Fig-
ure 3).
Four tumors (patients nos. 1 to 4) showed a typi-
cal acinar pattern, reminiscent of normal pancreatic
acinar tissue. Their mitotic activity was low (three of
four tumors with less than one mitosis in 10 ran-
domly selected high-power fields), and they had
K12SHind AAACTTGTGGTAGTTGAAGC-O,
5' CATGTTCTAATATAGTCACATTTTCATTATTTTTATTATAAGGCCTGCTGAAAATGAACTGAATATAAACTTGTGGTAGTTGGAGCT
GGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAATATGATCCAACA 3'
'- AGCGCATCCGTTCTCACGGAAC K12AMbo '4-ACCTGCTTATACTAGGTTGT K12A2
<4-ACTGCATCCGTTCTCACGGAAC K12AHinc
4- CGGCATCCGTTCTCACGGAAC K12ABan
Figure 2. Oligonucleotide primers used it this study. Sequentces are the same as those described by Mitsudomi et al (1991), and their orientation is
shoun relative to the sence strand of Ki-ras. Mismatched nucleotides in the primers are underlined.
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Figure 3. Histological patterns of acinar cell
carcinomas. A: Typical acinarpattern (patient
no. 3). B: Mixed acinar-solid pattern (patient
no. 5). C: Solid pattern (patient no. 15). H&E,
original magnification, 250X (A,C); 10OX (B).
round nuclei of uniform size within abundant eosino-
philic cytoplasm, which was finely granular PAS-
positive in its apical portion. Some tumors showed
areas with dilated acini forming a microglandular
pattern.
In nine tumors, (patients nos. 5 to 13), typical aci-
nar areas alternated with trabecular and solid forma-
tions. The tumor cells were still rich in cytoplasm and
were usually PAS-positive, but the nuclei were some-
what irregular in size and seemed to be larger than in
the acinar category. Four of the nine tumors had less
than one mitosis per 10 high-power fields, another
four between one and five mitoses, and one more
than 10 mitoses. One tumor (patient no. 5) exhibited
in addition to an acino-trabecular pattern scattered
clusters of cells with pale cytoplasm, resembling
squamoid corpuscles in pancreatoblastomas.
Seven tumors (case nos. 14 to 20) displayed a
solid pattern reminiscent of low-grade endocrine tu-
mors. They usually showed necrotic areas. The cells
had rather scanty cytoplasm and contained vesicu-
lar nuclei with distinct nucleoli. Six of the seven tu-
mors had one to five mitoses or even more per 10
high-power fields.
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The two acinar cystadenocarcinomas were
largely composed of tubular and microglandular
complexes, microcysts as well as macrocysts of
varying size. The cells lining the cysts had either a
cylindric appearance or were cuboidal. The cyst
content was faintly PAS-positive and focally calci-
fied in one case.
Immunocytochemical Findings
All but one tumor stained strongly for at least one of
the following pancreatic enzymes: trypsin (21 of
22), lipase (19 of 22), chymotrypsin (13 of 22), and
phospholipase A2 (nine of 22) (Figure 4A). PSP was
expressed in 19 of 22 tumors, including one tumor
that otherwise was negative for all of the above-
mentioned pancreatic enzymes. None of the tumors
stained with the four antisera against a-amylase that
were used in this study (for control reactions see
below) (Figure 4B). Enzyme staining was demon-
strated in the apical portion of most cells in all tu-
mors with acinar pattern, whereas it was focal and
usually restricted to single cells in tumors with solid
patterns. The most intense immunoreactivity was
obtained with our own antisera against trypsin and
lipase and the commercial antiserum against PSP.
The polyclonal and monoclonal antisera against
trypsin purchased from Ventrex were only positive in
one-third and two-thirds, respectively, of the tumors
that stained with our own antiserum against trypsin.
All tumors positive for the keratin marker CAM 5.2
(demonstrating the presence of keratins 8, 18, and
19) showed a distinct membranous staining.
Among the markers that were found to be nega-
tive in all or almost all tumors were the mucin anti-
gen Ml (O of 22), CEA (one of 22), and AFP (one of
22). The only CEA- and AFP-positive tumor was of
solid pattern (patient no. 19). Positivity for CA 19.9
and B72.3 (TAG 72) was recorded in nine and
seven tumors respectively, most of them (eight of
nine) belonging to the tumors with a mixed or solid
pattern. This was also true for AAT expression found
in 13 tumors.
Eight tumors, all with a mixed or solid pattern,
were positive for at least one of the three neuroen-
docrine markers used (Figure 5). Identical results
were obtained with the two synaptophysin antisera.
In all but two tumors, synaptophysin and chromog-
ranin A were expressed simultaneously. In two tu-
mors, somatostatin (but no other pancreatic hor-
mone) was identified in the neuroendocrine cells,
which were very numerous in these cases. Distribu-
tion of the neuroendocrine cells was diffuse in
seven tumors and focal in one (patient no. 5), where
the endocrine cell clusters corresponded to the en-
zyme negative cell nests observed in the hematoxy-
lin and eosin sections. Double staining for synapto-
physin and trypsin was performed in one tumor with
a large number of scattered neuroendocrine cells
(patient no. 19). Most of the stained cells showed
Figure 4. Tumor with an acinarpattern show-
ing a strong positivity for phospholipase A2
(patient no. 12) (A); and negative staining for
a-amylase (patient no. 15) (B). Note that the
normal acinar (NA) tissue stains positive with
amylase. Original magnification, 250X (A,B).
AMIIY]
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Figure 5. Serial sections of an acinar cell car-
cinoma (patient no. 19) showing immunoreac-
tivity to exocrine and neuroendocnine markers:
(A) trypsin; (B) PSP; (C) synaptophysin; and
(D) chromogranin A. Oniginal magnification,
600X (A,B,C,D).
only one reaction product (ie, either blue stain for
trypsin or brown stain for synaptophysin) but in oc-
casional single cells coexpression of synaptophysin
and trypsin was observed (Figure 6). Immunocy-
tochemical screening for mutant p53 overexpres-
sion gave a negative result in all tumor specimens
tested from 19 patients, whereas control tissues re-
acted appropriately.
The specificity of the staining reactions for the
pancreatic enzymes and PSP was tested on normal
tissue specimens from the pancreas (n = 4),
duodenum (n = 4), and liver (n = 3), as well as
specimens from pancreatic endocrine tumors (n =
5) and ductal adenocarcinomas (n = 10). The re-
sults were as follows: normal pancreatic acinar cells
were intensely labeled with our own antisera against
a-amylase, lipase, trypsin, and chymotrypsin, and
the commercially available antiserum against PSR
Three of these antisera (against lipase, trypsin, and
PSP) also stained single duct cells, but none of the
antisera labeled islet cells. From the other commer-
cially available antisera against a-amylase and
trypsin, only the amylase antiserum from Chemicon
and the polyclonal and monoclonal trypsin antisera
from Ventrex yielded a positive reaction in the aci-
nar cells and also some duct cells. The amylase-
antisera from DRG Instruments (Marburg, Germany)
and Binding Site (Birmingham, UK) failed to stain
normal acinar tissue. The duodenal mucosa was
negative for lipase and chymotrypsin (own anti-
sera), but Paneth cells at the base of the duodenal
crypts were positive for trypsin and PSP. The normal
liver tissue as well as the pancreatic endocrine tu-
mors were negative for all antisera tested. The duc-
tal adenocarcinomas were negative for amylase
and chymotrypsin, but some of the tumors were im-
munoreactive, although only weakly, for trypsin (five
of 10), lipase (two of 10), and PSP (two of 10).
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Figure 6. Double immtunostaining of acinar cell
carcinoma (patient no. 19): single cells sbou' co-
expression of synaptophvsin (broun stain) and
trypsin (blue staini) (arrous). Original magnifica-
tion, 600X.
Preabsorption of our own trypsin antiserum with
trypsin completely abolished the staining reaction in
normal and neoplastic pancreatic acinar cells as
well as in Paneth cells of the duodenal crypts, but
not in normal and neoplastic duct cells from the
pancreas. These results confirm a previous study13
in which trypsin was also found in neoplastic pan-
creatic duct cells. Moreover, the results suggest that
the positive reactions for trypsin in normal pancre-
atic duct cells and ductal adenocarcinomas are due
to a cross-reactivity, probably with mucins or other
duct cell antigens that may be present in small
amounts in the enzyme preparations used for immu-
nization.
Electronmicroscopical Findings
In the nine tumors from which tissue was available
for ultrastructural examination, rather uniform
electron-dense granules were observed that were
commonly oriented toward the luminal space of aci-
narlike complexes. These granules were round and
their diameters ranged between 200 and 700 nm.
Their appearance was consistent with that of normal
pancreatic zymogen granules. The zymogen nature
of the granules was demonstrated by a positive im-
munogold labeling for trypsin in one tumor (case
no. 14) (Figure 7). No neuroendocrine secretory
granules were identified in the available tumor
specimens. In six of the nine tumors, the absence of
neuroendocrine granules corresponded with nega-
tive immunostaining for neuroendocrine markers. In
three tumors (case nos. 13, 14, and 18) that exhib-
ited scattered neuroendocrine cells at the light mi-
croscopical level, the failure to detect the same
cells at the ultrastructural level may probably be ex-
plained by sampling error. In addition to zymogen
granules, most tumor cells displayed a well-
developed rough endoplasmic reticulum and usu-
ally some microvilli at the apical surface.
Molecular Analysis
Formalin-fixed tumor specimens from 16 patients
with acinar cell carcinoma were successfully ampli-
fied and screened for the presence of the wild-type
sequence at codon 12 of Ki-ras. One tumor (case
no. 14) showed only partial digestion of the ampli-
fied DNA with Banl, suggesting that a heterozygous
mutation was present in the restriction site. This tis-
sue was subjected to designed restriction fragment
length polymorphisms analysis to identify the muta-
tion, and DNA amplified with K12S and K12AHinc
could be partially digested with Hincll (Figure 8).
These results indicate that this case was heterozy-
gous with one Ki-ras allele carrying the sequence
GTT in place of the wild type GGT at codon 12.
Discussion
In the present study, we found that pancreatic aci-
nar cell carcinomas present a diverse histological
spectrum with a typical acinar pattern at one end
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Figure 7. E/lecti-on microscopy rev,eals clarge z -
mogenlike granules, uwich were commonlv onr-
entatecl touward acinar lunminta. Inset: positive
immunoglold labeling Jbr trypsin (patient nio.
14). Original tnagiif/ication, 6o 340X; inset,
12. OOOX.
and a solid endocrinelike appearance at the other.
Moreover, one-third of the tumors, most of them with
solid pattern, expressed neuroendocrine cell lin-
eage markers as well as markers that have been
associated with the duct cell phenotype. However,
despite the diversity in the phenotypical appear-
ance of the tumors, other findings, such as the con-
sistent demonstration of at least one of the pancre-
atic enzymes tested, the very low Ki-ras point
mutation rate at codon 12 and the failure to identify
overexpression of p53 suggest that the tumors
nonetheless represent an entity different from neu-
roendocrine as well as other types of exocrine neo-
plasms of the pancreas.
The view that acinar cell carcinomas constitute a
distinct entity among tumors of the pancreas is also
maintained in a recently published study by Klim-
stra et all which gives a detailed description of the
clinicopathological features in 28 cases of acinar
cell carcinomas. Whereas many of their findings are
confirmed by our own data (ie, age and sex distri-
bution, presentation with metastasis, poor progno-
sis, large size, gross invasion of duodenum, stom-
ach, or spleen), others are extended (histological
and immunocytochemical spectrum) or new (Ki-ras
codon 12 mutation, p53 protein overexpression).
As the histological differentiation varied consider-
ably between our acinar cell carcinomas, we sepa-
rated the tumors according to their microscopic fea-
tures into tumors displaying a pure acinar pattern,
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Figure 8. Detection activating Ki-ras codon
12 mutation in acinar cell carcinoma AC14
(patient no. 14). This case shows a heterozy-
gous G-TtransveeNion mutation at codon 12 re-
sulting in amino acid substitution Valine
(GTT) for the normal Glycine (GGT) in the Ki-
ras protein.
tumors with a mixed pattern, and tumors with a
solid pattern. Most tumors (nine of 20) presented
with a mixed pattern in which acinar structures alter-
nated with microglandular, trabecular, and solid ar-
eas. These tumors usually had a higher mitotic rate
than the tumors with a pure acinar differentiation
(four of 20). Because of the presence of typical aci-
nar structures with apical PAS positivity in the
former tumors, they created little diagnostic prob-
lems. This was also true for the two cystic variants
of acinar cell carcinoma, despite their special gross
appearance, which as in the case of Cantrell et a122
rather suggested a cystic pancreatic tumor of duct
cell23 than of acinar cell origin. The diagnosis in the
seven tumors with a solid pattern was difficult, rem-
iniscent of a low-grade endocrine tumor rich in mito-
ses. In these neoplasms, it was necessary to estab-
lish the diagnosis by immunocytochemistry and/or
electron microscopy.
Immunocytochemical analysis demonstrated aci-
nar cell differentiation in all tumors of this series. Li-
pase, phospholipase A2, trypsin, chymotrypsin,
and PSP, secreted by normal acinar cells and
stored in zymogen granules3'24-26 were present in
all tumors although in varying intensity, frequency,
and cellular distribution, depending on the histolog-
ical differentiation. Whereas in tumors with acinar
and mixed patterns, the markers were expressed
by many (or most) cells, usually only scattered cells
were stained in tumors with solid patterns. As in our
previous work,3 we again failed to detect amylase in
any of the tumors, although we used four different
antisera. This result, which is in contrast to Klimstra
et al's findings,7 might be explained by the possibil-
ity that the tumors' amylase differ in conformation
and antigenicity from normal a-amylase and is
therefore not recognized by the antisera used in this
study.
PSP was present in all but three tumors of this se-
ries. Recent studies suggest that PSP27 and a sec-
ond protein called pancreatic thread protein28 are
encoded by the human regenerating gene (reg).29
In the normal human pancreas, PSP26 as well as
reg messenger RNA and reg protein30 have been
localized to the acinar cells and in particular to the
zymogen granules. The reg protein was also found
to be expressed by an acinar cell carcinoma and a
pancreatoblastoma.30 These results together with
our data suggest that PSP and reg protein can be
added as a marker of acinar cell differentiation in
pancreatic tumors. The relationship between PSP/
reg protein and pancreatic enzymes is so far un-
clear, but a possible function as a stabilizer of pan-
creatic juice has been discussed.26
With respect to the tissue and cell specificity of
PSP/reg protein and trypsin, our findings and those
of Kimura et al30 and Lechene de la Porte et a126 in-
dicate that both PSP/reg protein and trypsin are
present in the intestinal Paneth cells. Weak immu-
noreactivity to PSP/reg protein, trypsin, and lipase
was in addition detected in some ductal adenocar-
cinomas 13,30 and solid-cystic tumors of the pan-
creas.30 As to the trypsin reactivity we observed in
five of 10 ductal adenocarcinomas and single duct
cells of the normal pancreas, we were able to show
that it was most likely due to cross-reactivity of the
antiserum with an as yet unidentified antigen, be-
cause preabsorption of the trypsin antiserum with
trypsin abolished the reaction product in Paneth
cells as well as in normal and neoplastic acinar but
not in duct cells. Taken together, these results make
clear that PSP and trypsin (and probably other pan-
creatic enzymes as well) are not entirely specific,
but reasonably good markers for pancreatic acinar
cells.
Electron microscopy revealed in most published
cases of acinar cell carcinomas large secretory
vesicles corresponding to zymogen granules.4'11
Our ultrastructural results confirm this notion. Immu-
noelectron microscopic analysis in addition estab-
lished the zymogen nature of the granules by local-
izing trypsin to the granule content.
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The acinar cell carcinomas were found to ex-
press a number of markers that they share with
other exocrine pancreatic tumors. Most commonly
expressed were CA19.9 and B72.3, which are
known to be positive in almost all ductal
adenocarcinomas.331-33 CEA and the mucin anti-
gen Ml, which are also found in more than 90% of
the ductal adenocarcinomas, 17,34,35 were, however,
either rarely present (CEA) or absent (Ml) from the
acinar cell carcinomas. AFP, which is frequently de-
tectable in pancreatoblastomas936 may also occur
in acinar cell carcinomas;30'37'38 but, according to
Klimstra et al's and our results, only in low fre-
quency. a-antitrypsin has been regarded a marker
of solid-cystic (papillary cystic) tumors of the pan-
creas,3'39 although it is also commonly expressed in
acinar cell carcinomas. However, it is important to
note that the a-antitrypsin positivity in acinar cell
carcinomas was always diffuse and thus different
from the patchy distribution of a-antitrypsin globules
that occur inside and outside the cells in solid-
cystic tumors.3'39
The appearance of endocrine cells in association
with ductal adenocarcinomas of the pancreas is
rather rare but may occur.40<2 Acinar cell carcino-
mas were generally thought to represent a re-
stricted pathway of differentiation and express only
cell lineage markers of the acinar cells.3'13 Sporadic
cases of mixed acinar-endocrine cell tumors of the
pancreas have been described,43'44 but these
cases may be disputable because they are based
solely on electron microscopic analysis without con-
comitant immunolabeling for specific vesicle mark-
ers. However, recent studies on the cell line AR 42J,
which derives from a rat pancreatic acinar carci-
noma and is widely used as an in vitro system for
functional studies of exocrine pancreatic acinar
cells, have convincingly demonstrated that these
cells contain both zymogen granules and small
neuroendocrine vesicles and express classical neu-
roendocrine markers.12 These experimental findings
can now be partly confirmed in human acinar cell
tumors. Both in Klimstra's study as in our investiga-
tion, 42% and 36% of the tumors, respectively,
showed immunocytochemical evidence of neuroen-
docrine differentiation. So far this finding could not
be corroborated at the ultrastructural level, most
probably because of the difficulty in distinguishing
clearly between zymogen granules from neuroendo-
crine vesicles in neoplastic cells. Coexpression of
neuroendocrine markers and pancreatic enzymes in
the same cell was therefore only examined at the
light microscopical level using the double staining
technique. This investigation (performed in only one
tumor) revealed that synaptophysin and trypsin
were expressed in different cells and only occasion-
ally seemed to occur in the same cell. Although this
finding is preliminary, it may suggest that in acinar
cell carcinomas only a certain cell population ac-
quire the ability to differentiate into endocrine cells,
whereas the other cells largely maintain their acinar
features.
Hall and Lemoine45 showed that acinar cells
when cultured in vitro rapidly transdifferentiate into
a ductal phenotype. This capacity of the acinar
cells may explain the common expression of
CA19.9 and B 72.3 in acinar cell carcinomas, which
are generally regarded as duct cell markers. How-
ever, if there is indeed such a differentiation of aci-
nar cell carcinomas toward ductal adenocarcino-
mas, it seems to be incomplete, because the
tumors not only lacked any mucin production but
also failed to show the Ki-ras point mutation at
codon 12 and the overexpression of the p53 protein
at the same high frequency as it is known to occur
in ductal adenocarcinomas.14 18,4649This suggests
that the acinar cell carcinomas, despite their obvi-
ous capacity to differentiate into several directions,
constitute an entity with a tumorigenesis that is dif-
ferent from that of the ductal adenocarcinomas.
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